OSTEOSARCOMA

This early-phase study tests a personalized cell therapy for children and young adults (up to age 26) with solid tumors that have come back or not responded to standard treatment. The therapy uses the patient's own immune cells, modified to recognize and attack a protein called B…

This early-stage study tests a treatment made from a patient's own immune cells, modified to recognize and attack solid tumors. It includes children and young adults (ages 1–30) whose cancer has returned or not responded to standard therapy. The goal is to find a safe dose and se…

This study tests a combination of two drugs, cobolimab and dostarlimab, in children and young adults (up to age 21) with advanced solid tumors that have not responded to other treatments. The goal is to find the safest dose and see if the drugs can shrink tumors. The study involv…

This study tests a drug called cabozantinib in children and young adults (up to age 30) with rare cancers like sarcomas, Wilms tumor, and others that have come back or not responded to standard therapy. The drug works by blocking enzymes that help tumors grow and form blood vesse…

This study tests a new drug called HS-20093 against a standard chemotherapy combination (gemcitabine plus docetaxel) in people with osteosarcoma (bone cancer) that has not responded to at least two prior treatments. About 117 participants aged 12 and older will be randomly assign…

This study tests a drug called regorafenib in people aged 9 to 21 with bone cancer (osteosarcoma or Ewing sarcoma) that has come back or not responded to standard therapy. The goal is to see if the drug can help control the cancer and to find the right dose. Researchers will also…

This early-phase study tests an experimental drug called CLR 131 in 30 children, adolescents, and young adults whose solid tumors, lymphoma, or brain tumors have returned or not responded to standard treatments. The main goal is to find a safe dose and check for side effects. Par…

This study tests a combination of two drugs, regorafenib and nivolumab, in people with osteosarcoma (a type of bone cancer) that has come back or not responded to treatment. The goal is to see if this combination can stop the cancer from growing longer than regorafenib alone. Abo…

This early-stage study tests a two-part treatment for osteosarcoma that has not responded to standard therapy or has returned. First, a patient's own immune cells are collected, modified in a lab to become CAR T cells, and infused back. Then, a special marker drug is given that a…

This study tests whether two drugs, olaparib and ceralasertib, can help control osteosarcoma that has come back or not responded to treatment. It includes 63 people aged 12 to 40. The goal is to see if the combination can stop the cancer from growing for at least 4 months.

This study tests two immunotherapy drugs, nivolumab and azacitidine, in people whose osteosarcoma (a type of bone cancer) has come back and can be removed with surgery. The goal is to see if these drugs are safe and help keep the cancer from returning after surgery. About 21 adul…

This trial tests whether adding the drug mifamurtide to standard chemotherapy after surgery helps people with high-risk osteosarcoma (a type of bone cancer) live longer without the cancer coming back. The study includes 60 patients aged 2 to 50 with newly diagnosed, aggressive os…

This early-stage study tests a new treatment for advanced osteosarcoma and neuroblastoma that has not responded to standard therapies. Researchers take a patient's own immune cells, add a special receptor to help them recognize and attack cancer cells, and combine them with a chi…

This study tests a drug called DS-8201a (trastuzumab deruxtecan) in people aged 12 to 39 with HER2-positive osteosarcoma that has returned. The drug works like a smart bomb, attaching to HER2 on cancer cells and delivering chemotherapy directly to them. The main goal is to see if…

This study looks at whether a special PET scan using a natural substance called methionine can help doctors see tumors in children and young adults with cancer. About 500 participants will get the scan to check if it can find tumors, tell how aggressive they are, and tell leftove…

This early-phase trial tests whether the drug glucarpidase can safely lower the toxic side effects of high-dose methotrexate in adults with osteosarcoma (a type of bone cancer). The study involves 12 participants and aims to see if the drug helps patients complete their planned c…

This study looks at tumor samples from people with bone cancer (osteosarcoma) to understand why some tumors don't respond to chemotherapy. Researchers will test these samples in the lab and also study blood markers. The goal is to learn more about drug resistance, not to test a n…

This study follows 500 adults aged 18 to 65 who finished their first chemotherapy treatment for certain cancers and are in remission. Over 5 years, researchers will check for 19 possible late side effects, like heart or lung problems, and offer follow-up care. The goal is to bett…